Who owns Definium Therapeutics, Inc. (DFT)? Elite investor 13F holders

3 tracked elite investors reported holding Definium Therapeutics, Inc as of 2026-09-30, including Duquesne Family Office, D.E. Shaw, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Duquesne Family OfficeDefinium Therapeutics IncSHARE2026-06-302026-08-14 00:00:0016774000.00 USD356600.000000SharesbuyOriginal filing
D.E. ShawDefinium Therapeutics IncSHARE2026-09-302026-11-16 00:00:006063148.00 USD159305.000000SharesreduceOriginal filing
Gotham Asset ManagementDefinium Therapeutics IncSHARE2026-09-302026-11-16 00:00:000.00 USD0.000000SharesexitedOriginal filing
Ancora Advisors / Ancora HoldingsDefinium Therapeutics IncSHARE2026-09-302026-11-17 00:00:009819.00 USD258.000000SharesholdOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown